Innovent ditches low-value stake sale after investor outcry
The biopharmaceutical company had planned to sell a 20% stake in its international unit to the group’s founder, but the cheap price sparked a crisis of market confidence Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
